TDP-43, formally TAR DNA-binding protein 43, is a 414-amino-acid protein that in healthy cells lives mainly in the nucleus, binding thousands of RNA transcripts and steering their splicing, stability, export and translation. In disease it defects: in roughly 97 percent of ALS cases and about half of frontotemporal dementia cases, TDP-43 abandons the nucleus, becomes hyperphosphorylated and ubiquitinated, and precipitates into cytoplasmic inclusions that form the pathological signature of the illness. Under stress, the protein also shuttles into cytoplasmic stress granules, one reason scientists have long suspected a tie between TDP-43 and granule pathology. Rare inherited point mutations in the TDP-43 gene cause ALS outright. One of them, G376D — a glycine-to-aspartic-acid substitution at position 376 in the protein’s glycine-rich C-terminal region — drives cytoplasmic mislocalization and has been linked to mitochondrial and lysosomal malfunctions. What has remained unclear is how a nuclear RNA-binding protein could sabotage lysosomal biology at all, because TDP-43 was not known to hold a direct foothold in the trafficking system that delivers autophagosomes to their destination. The new study supplies that foothold.

The team attacked the problem from the autophagy side. They silenced TDP-43 in cultured cells and surveyed what happened to known components of the degradative machinery. One protein stood out immediately: RILP, the Rab-interacting lysosomal protein, a well-characterized effector of RAB7A. When TDP-43 disappeared, RILP abundance fell sharply — not a minor fluctuation, but a drop deep enough to leave cells short of the adaptor they need to handle late endosomes and autophagosomes. The same collapse followed expression of the ALS-causative G376D mutant, and with it the cells’ autophagic flux — the complete, quantifiable throughput of the autophagy pathway, from autophagosome formation to lysosomal degradation — was compromised. A stalled flux is more dangerous than it sounds: autophagosomes keep forming and capturing cargo, but the cargo is never digested, so the cell fills with undegraded protein aggregates and damaged organelles. Notably, RILP messenger RNA levels were largely preserved, hinting that TDP-43 was acting not on the RILP gene’s transcript but on a later stage of protein production.

RILP’s job description explains why losing it is catastrophic. RAB7A is a molecular switch anchored on late endosomes and autophagosomes, and RILP is one of its principal effectors: through RILP, RAB7A recruits the dynein–dynactin motor complex that hauls vesicles retrograde along microtubules and helps position them for fusion with lysosomes. Without sufficient RILP, vesicles that should converge on lysosomes idle in the cytoplasm, loaded but undelivered. The damage radiates into a second ALS-relevant system: stress granules, the transient, membraneless assemblies of stalled messenger ribonucleoprotein particles that form when cells are under stress and that must either dissolve or be cleared once the crisis passes. Granules that linger become potential breeding grounds for the pathological aggregates seen in ALS. In TDP-43-compromised cells, stress granule markers piled up — consistent with a clearance system too weakened to keep granule turnover on schedule, and with the homeostatic balance between granule formation and dissolution tipping toward persistence.

The decisive test was a rescue. When the researchers forced extra RILP into TDP-43-depleted cells, or into cells expressing the G376D mutant, autophagic flux rebounded and stress granule marker levels dropped. The result established RILP as an effector acting downstream of TDP-43 in this pathway and demonstrated that RILP can overcome TDP-43 malfunctioning rather than merely suffering from it. The rescue also carried an immediate therapeutic implication: if TDP-43 toxicity flows in part through RILP depletion, then restoring RILP — whether by delivering the gene, stabilizing its synthesis, or manipulating the pathways that control it — might counteract several damaging consequences of the mutant protein at once instead of attacking each symptom separately. For a disease in which hundreds of downstream failures have been catalogued, a single upstream node with pleiotropic rescue effects is precisely the kind of target that drug developers prize.

How TDP-43 governs RILP emerged from polysome profiling, a technique that separates messenger RNAs by centrifugation according to how many ribosomes are riding on them; ribosome-heavy fractions sediment farther, marking transcripts that are being translated efficiently. In TDP-43-depleted cells, RILP mRNA shifted away from these heavy polysomes into lighter fractions containing few ribosomes per transcript. Less RILP protein was therefore produced from the same amount of messenger RNA — a translational defect, not a transcriptional one. The finding adds an unexpected item to TDP-43’s already crowded portfolio: beyond regulating RNA splicing, stability and microRNA processing, the protein evidently safeguards the translational efficiency of a key lysosomal-trafficking gene. Because TDP-43 binds thousands of transcripts, the authors suggest that other effectors of cellular logistics may likewise depend on its translational stewardship, with RILP simply the first to be caught in the act.

That mechanism opened a strikingly simple experimental door. The team found that L-leucine — an essential amino acid best known for activating the nutrient-sensing kinase complex mTORC1 — restored RILP levels both in TDP-43-depleted cells and in cells expressing the G376D mutant. The rescue vanished when mTOR signaling was inhibited or when protein synthesis was blocked, confirming that leucine acts by re-engaging mTOR-dependent translation rather than through any unrelated route. In effect, a nutrient signal could partially substitute for the translational control that TDP-43 normally provides. The authors frame this as mechanism, not medicine: the experiments were conducted in cell and neuron models, and leucine supplementation is not being proposed as an ALS therapy. Even so, the result sketches a pharmacological strategy — biasing the translational apparatus toward RILP production — that could in principle be pursued with molecules acting on the same pathway more precisely and safely.

The strongest evidence came from human motor neurons. Working with the Cellular Reprogramming Unit of the Fondazione IRCCS Casa Sollievo della Sofferenza, the team reprogrammed cells from patients carrying the G376D mutation into induced pluripotent stem cells and then differentiated them into motor neurons — precisely the cell type that degenerates in ALS. In these patient-derived neurons, RILP was again downregulated and autophagic flux again defective, faithfully reproducing the defects seen in simpler models. The rescue held there too: boosting RILP improved autophagy and increased cell viability in the mutant motor neurons. Behind the data stands a human story. The paper is dedicated to the memory of Professor Vincenzo La Bella, who directed the ALS Clinical Research Center in Palermo, supplied the patient cells and championed the project before his premature death. The samples were collected under approved ethical protocols with informed consent, in accordance with the Declaration of Helsinki.

The final piece was physical. Co-immunoprecipitation experiments showed that TDP-43 sits in molecular complexes containing both RILP and RAB7A, but only the RILP contact is direct — RAB7A is drawn in through its effector. Mapping the interface revealed that binding occurs between RILP’s C-terminal region and amino acids 320 to 346 of TDP-43, a stretch inside TDP-43’s C-terminal low-complexity domain, the same neighborhood where pathogenic mutations, including G376D, cluster. The surprise came when the mutant was tested: TDP-43G376D bound RILP more strongly than the wild-type protein. A stickier grip sounds benign, but its consequences were destructive. Cells expressing the mutant showed a weakened interaction between RILP and RAB7A, implying that the pathogenic protein sequesters RILP into complexes where it can no longer serve RAB7A. The mutation thus attacks the axis on two fronts simultaneously — it binds RILP too tightly and misdirects it, and it suppresses RILP synthesis through translational repression.

Taken together, the study defines a TDP-43–RILP–RAB7A axis in which an RNA-binding protein, a lysosomal adaptor and a Rab GTPase operate as one functional circuit — and shows how a single ALS mutation can cut that circuit at multiple points at once. Such convergence may explain why mitochondrial, lysosomal and stress granule defects so often travel together in ALS tissue, and why models that target any single process have struggled to capture the full disease. It also marks where future interventions could aim: raising RILP abundance, protecting the RILP–RAB7A interface, or reactivating RILP translation through mTOR-sensitive pathways. The authors caution that the work remains preclinical — rescue experiments in cultured cells and patient-derived neurons do not yet constitute a therapy, and delivering protein-restoring treatments to spinal motor neurons remains one of neuroscience’s hardest delivery problems. But the conceptual shift is substantial. After two decades centered on RNA misprocessing and protein aggregation, ALS biology now has a third pillar — TDP-43’s guardianship of the cell’s autophagy infrastructure — and a new, testable target.

TDP-43, or TAR DNA-binding protein 43, has predominantly been studied in the context of neurons, where its aggregation and dysfunction are hallmarks of several neurodegenerative disorders. However, the UConn team has identified that reduced levels of TDP-43 in endothelial cells result in significant impairment of the blood-brain barrier’s integrity. Endothelial cells are specialized cells forming a tight monolayer lining the interior surface of blood vessels, and their role is critical in maintaining selective permeability—allowing nutrients to pass while keeping harmful substances from infiltrating brain tissue.

The research underscores that when TDP-43 levels fall below a critical threshold, endothelial cells lose their ability to maintain tight junctions, leading to gaps in the vascular walls. These gaps permit the uncontrolled entry of macromolecules and potentially neurotoxic substances from the bloodstream into the brain parenchyma, thereby accelerating inflammatory responses and neuronal damage. This vascular pathology could contribute directly to the progression and severity of neurodegenerative disease symptoms by disrupting the delicate homeostasis necessary for brain function.

To dissect these mechanisms, the researchers employed sophisticated genetically engineered mouse models. One model harbors a TARDBP mutation linked to familial forms of ALS and frontotemporal dementia, while the second model features targeted deletion of TDP-43 specifically in endothelial cells, sparing neurons and glial cells. Both models exhibited pronounced signs of blood-brain barrier breakdown, evidenced by increased vascular permeability and infiltration of inflammatory cells into brain tissue. These pathological changes were accompanied by behavioral deficits consistent with neurological dysfunction.

These findings expand the scope of TDP-43’s pathological impact beyond neurons, suggesting that its dysregulation in non-neuronal cells plays a substantial role in disease pathogenesis. The presence of TDP-43 aggregates in endothelial cells and ensuing barrier compromise may help explain the phenotypic variability observed clinically—for example, the differing degrees of paralysis in ALS compared to cognitive impairment in frontotemporal dementia, despite overlapping genetic underpinnings.

Remarkably, most cases of ALS and frontotemporal dementia lack identifiable mutations in the TARDBP gene, yet still exhibit TDP-43 protein dysfunction. This observation points to the existence of additional, as yet unidentified endogenous or environmental factors that may disrupt TDP-43 function. Dr. Ashok Cheemala, a lead investigator on the project, emphasizes the need to explore these non-genetic contributors. The team aims to uncover other genetic or molecular regulators whose dysfunction could provoke TDP-43 anomalies in endothelial cells, offering novel therapeutic targets to mitigate disease progression.

An intriguing facet of TDP-43 pathology is its prion-like behavior: the protein tends to misfold and aggregate, forming intracellular inclusions reminiscent of infectious proteins that propagate dysfunction through cell-to-cell transmission. The researchers are actively investigating whether TDP-43 dysfunction in endothelial cells can spread to adjacent neuronal and glial populations. Since the blood vessels are intimately intertwined with neurons and astrocytes, the possibility of a pathogenic cascade initiated by the endothelium holds significant implications for understanding disease chronology and intercellular communication.

Early dysfunction of endothelial TDP-43 might thus represent a critical initiating event in neurodegenerative disease pathogenesis, disrupting vascular integrity before substantial neuronal loss occurs. Unraveling the molecular basis of this early endothelial involvement could transform therapeutic strategies focused on preserving or restoring the blood-brain barrier’s protective function—a compelling avenue to slow or halt the advance of ALS, frontotemporal dementia, and Alzheimer’s disease.

Equally important, the UConn researchers propose that therapeutic approaches targeting endothelial cell health could complement neuron-centric treatments, addressing the multifaceted nature of neurodegeneration. Protecting the vasculature may not only reduce neuroinflammation and toxin infiltration but also maintain the brain’s metabolic and signaling environment conducive to neuronal survival.

The study draws upon extensive experimental methodologies, including transgenic mouse models, immunohistochemistry, in vivo imaging of vascular permeability, and behavioral assays, rendering a comprehensive portrait of the pathological cascade triggered by TARDBP mutations at the cellular and systems levels. These data collectively emphasize the indispensable role of endothelial TDP-43 in neurovascular homeostasis and disease.

This paradigm shift opens new scientific frontiers in neurological research, urging a broader investigation of how blood-brain barrier integrity intersects with proteinopathies characteristic of neurodegenerative diseases. It also highlights the imperative for cross-disciplinary collaboration between vascular biology, neurology, and molecular genetics to unravel the complex etiology of these disorders.

Looking forward, the University of Connecticut team is poised to delve deeper into the molecular events that provoke TDP-43 dysfunction in endothelial cells absent genetic mutations and to identify genetic modifiers that might confer vulnerability or resilience. Such knowledge promises to accelerate the development of innovative therapeutics targeting early disease mechanisms, potentially yielding significant clinical benefits for patients grappling with these currently incurable brain diseases.

The implications of this study resonate beyond the lab, offering hope that addressing vascular contributions and protein dysfunction in unison could redefine the approach to some of the most devastating neurodegenerative conditions known to medicine.

Subject of Research: Animals

Article Title: Amyotrophic lateral sclerosis and frontotemporal dementia mutation reduces endothelial TDP-43 and causes blood-brain barrier defects

News Publication Date: 16-Apr-2025

Web References: 10.1126/sciadv.ads0505

Keywords: Neurological disorders, Amyotrophic lateral sclerosis, Neurodegenerative diseases, Alzheimer disease